Sema4a-KO Mouse
一般名
Sema4a-KO
製品ID
S-KO-20337
背景情報
C57BL/6JCya
系統ID
KOCMP-20351-Sema4a-B6J-VB
状況
このマウス系統を論文で使用する場合は、「Sema4a-KO Mouse(カタログ番号S-KO-20337)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Sema4a-KO
系統ID
KOCMP-20351-Sema4a-B6J-VB
遺伝子名
製品ID
S-KO-20337
遺伝子別名
SemB, Semab
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 3
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000029700
NCBIトランスクリプトID
NM_013658
ターゲット領域
Exon 7~9
有効領域の大きさ
~2.0 kb
遺伝子研究の概要
Sema4a, a member of the semaphorin family, was initially recognized as an axon guidance factor in the nervous system. It is preferentially expressed on immune cells and has been shown to play crucial roles in immune function, angiogenesis, and cell-cell interactions. Sema4a has 4 types of receptors: Plexin D family, Plexin B family, Tim-2, and Nrp-1 [3].
In prostate cancer, Sema4a was highly expressed in tissues, correlated with Gleason scores and distant metastasis. Genetic depletion of Sema4a prevented lung metastasis in PCa xenograft models, indicating its role in promoting cancer invasion through inducing Epithelial-mesenchymal transition (EMT) of PCa cells and establishing a positive loop with IL-10 in stromal cells [1].
In multiple sclerosis (MS), approximately one-third of patients with high Sema4a levels were unresponsive to IFN-β treatment. In an animal model of MS (EAE), administration of Sema4A concurrently with IFN-β abrogated the efficacy of IFN-β, as Sema4a promoted Th1 and Th17 differentiation and increased adhesive activation of T cells to endothelial cells [2,6]. In the effector phase of adoptively transferred EAE model, Sema4a-deficient (Sema4a KO) recipient mice receiving Th17-skewed WT myelin oligodendrocyte glycoprotein (MOG)-specific encephalitogenic T cells showed a reduced clinical score, suggesting Sema4a is involved in accelerating Th17-cell-mediated neuroinflammation in the effector phase [4].
In non-small cell lung cancer (NSCLC), Sema4a-positive tumors responded better to anti-programmed cell death 1 (PD-1) antibody. Sema4a promoted cytotoxicity and proliferation of tumor-specific CD8+ T cells in murine models, potentially being a biomarker for predicting and promoting ICI efficacy [5].
In conclusion, Sema4a plays essential roles in immune function, angiogenesis, and cancer progression. Studies using Sema4a KO mouse models have revealed its significance in prostate cancer invasion, MS pathogenesis, and the response to certain cancer immunotherapies. These findings contribute to a better understanding of the underlying mechanisms of these diseases and may provide potential therapeutic targets.
References:
1. Liu, Xiao, Tan, Weiwei, Wang, Weiqi, Wang, Lin, Zhou, Wei. 2023. SEMA4A promotes prostate cancer invasion: involvement of tumor microenvironment. In Journal of Cancer, 14, 2633-2643. doi:10.7150/jca.86739. https://pubmed.ncbi.nlm.nih.gov/37779872/
2. Nakatsuji, Yuji. . [Sema4A as a biomarker predicting responsiveness to IFN β treatment]. In Rinsho shinkeigaku = Clinical neurology, 54, 972-4. doi:. https://pubmed.ncbi.nlm.nih.gov/25519959/
3. Ito, Daisuke, Kumanogoh, Atsushi. 2016. The role of Sema4A in angiogenesis, immune responses, carcinogenesis, and retinal systems. In Cell adhesion & migration, 10, 692-699. doi:. https://pubmed.ncbi.nlm.nih.gov/27736304/
4. Koda, Toru, Namba, Akiko, Kinoshita, Makoto, Mochizuki, Hideki, Okuno, Tatsusada. 2020. Sema4A is implicated in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase. In Journal of neuroinflammation, 17, 82. doi:10.1186/s12974-020-01757-w. https://pubmed.ncbi.nlm.nih.gov/32169103/
5. Naito, Yujiro, Koyama, Shohei, Masuhiro, Kentaro, Takeda, Yoshito, Kumanogoh, Atsushi. 2023. Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8+ T cell cytotoxicity and proliferation. In Science advances, 9, eade0718. doi:10.1126/sciadv.ade0718. https://pubmed.ncbi.nlm.nih.gov/37205755/
6. Koda, Toru, Okuno, Tatsusada, Takata, Kazushiro, Kumanogoh, Atsushi, Nakatsuji, Yuji. 2014. Sema4A inhibits the therapeutic effect of IFN-β in EAE. In Journal of neuroimmunology, 268, 43-9. doi:10.1016/j.jneuroim.2013.12.014. https://pubmed.ncbi.nlm.nih.gov/24439904/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
